OTCMKTS:ANTH Anthera Pharmaceuticals (ANTH) Stock Price, News & Analysis $0.0001 0.00 (0.00%) As of 07/17/2026 09:53 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsBuy This Stock About Anthera Pharmaceuticals Stock (OTCMKTS:ANTH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ANTH alerts:Sign Up Key Stats Today's Range$0.0001▼$0.000150-Day Range N/A52-Week Range$0.0001▼$0.0010Volume1,778 shsAverage Volume2,201 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Anthera Pharmaceuticals, trading on the OTC Markets under the symbol ANTH, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies for patients suffering from serious and rare inflammatory and autoimmune diseases. The company’s research and development efforts center on both biologic and small-molecule approaches designed to modulate key pathways in immune system dysfunction. Anthera’s strategy includes advancing lead candidates through late-stage clinical trials while exploring additional indications for its pipeline assets. The company’s most advanced asset, blisibimod, is a selective antagonist of B-cell activating factor (BAFF) that has been evaluated in clinical studies for systemic lupus erythematosus (SLE) and primary immune thrombocytopenia (ITP). Anthera has also pursued early-stage programs in fibrotic conditions and cardiovascular diseases, leveraging its proprietary protein engineering platform to generate novel candidates with potential best-in-class attributes. Collaboration agreements with academic institutions and contract research organizations support Anthera’s efforts to accelerate development timelines and broaden the clinical assessment of its technologies. Founded in the mid-2000s and headquartered in Hayward, California, Anthera has conducted multi-center trials across North America and Europe. The company’s management team comprises professionals with extensive experience in immunology, clinical operations and regulatory affairs, reflecting a commitment to rigorous clinical development and systematic advancement of its pipeline. Anthera’s operations include in-house research capabilities as well as strategic partnerships aimed at bridging the gap between laboratory discovery and commercial availability for patients in need.AI Generated. May Contain Errors. Read More Receive ANTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anthera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANTH Stock News HeadlinesAnthera Pharmaceuticals (OTCMKTS:ANTH) Shares Pass Above 200 Day Moving Average - Here's WhyJuly 9, 2026 | americanbankingnews.comSpaceX Lost $1 Trillion In A Week. So Why Did Bond Investors Rush To Lend It $20 Billion?June 23, 2026 | benzinga.comDon’t Buy SPCX Until You Read ThisSpaceX - ticker SPCX - just completed the biggest IPO in American history, raising $75 billion at a $1.8 trillion valuation. Goldman Sachs projects $474 billion in revenue by 2030, while Morgan Stanley goes further - $3.4 trillion by 2040. But NYU's Aswath Damodaran, Wall Street's 'Dean of Valuation,' called those projections 'a hallucination.' While every camera pointed at the rockets, Musk quietly placed a major bet on what he calls 'the world's biggest product' - something he believes could generate $30 trillion in revenue. Sixty of America's largest companies are making the same move, and the signal appeared in a quiet Friday SEC filing almost nobody noticed.July 18 at 1:00 AM | Porter & Company (Ad)ANTH Anthera Pharmaceuticals, Inc.April 24, 2025 | seekingalpha.comMACK - Merrimack Pharmaceuticals, Inc.June 28, 2023 | finance.yahoo.comIndustry Research Report on Cystic Fibrosis Drugs Market Share and Industrial Overview till 2030May 16, 2023 | marketwatch.comSystemic Lupus Erythematosus (SLE) Drugs Market Updates: 2023-2030 ForecastMay 16, 2023 | marketwatch.com2023-2030 Vasculitis Treatment Market Size (Growth and Outlook) includes Main Business Overview | with [124 Pages]May 5, 2023 | marketwatch.comSee More Headlines ANTH Stock Analysis - Frequently Asked Questions How have ANTH shares performed this year? Anthera Pharmaceuticals' stock was trading at $0.0001 at the beginning of 2026. Since then, ANTH stock has increased by 0.0% and is now trading at $0.0001. How were Anthera Pharmaceuticals' earnings last quarter? Anthera Pharmaceuticals, Inc. (OTCMKTS:ANTH) posted its quarterly earnings results on Monday, March, 5th. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.09. When did Anthera Pharmaceuticals' stock split? Anthera Pharmaceuticals shares reverse split before market open on Monday, May 1st 2017.The 1-8 reverse split was announced on Friday, April 28th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. How do I buy shares of Anthera Pharmaceuticals? Shares of ANTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Anthera Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Anthera Pharmaceuticals investors own include Ocular Therapeutix (OCUL), Novavax (NVAX), Bristol Myers Squibb (BMY), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO). Company Calendar Last Earnings3/05/2018Today7/18/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:ANTH CIK1316175 Webwww.anthera.com Phone(410) 350-1839Fax510-856-5597Employees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.23 The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (OTCMKTS:ANTH) was last updated on 7/18/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored‘We are at a hinge point in history’The new Fed chair just told Congress we are at a hinge point in history, signaling tighter policy ahead. When ...Weiss Ratings | SponsoredCentral banks bought 710 tonnes - this fund pays monthlyGold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...Investors Alley | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredThis same-day trade is getting a lot of attentionZero-days-to-expiration trades happen every single day - and most traders either ignore them or use them wrong...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredThe only metrics you should watch as a day trader.Day traders and swing traders don't need the same metrics - and using the wrong ones costs you edge. After 40 ...The TradingPub | SponsoredThe $250,000 Question Every American Should AskElon Musk's new banking platform is paying up to 15 times the national average interest rate while insuring de...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anthera Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anthera Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
